Ning Qian, Hou Lei, Meng Min, Pan Bo-Rong, Zhao Xin-Han
Department of Oncology, the First hospital Affiliated to School of Medicine of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China.
Int J Ophthalmol. 2011;4(5):552-7. doi: 10.3980/j.issn.2222-3959.2011.05.18. Epub 2011 Oct 18.
Most of the ocular tumors have poor prognosis, and they remain a difficult problem in the area of ophthalmology. With the rapid development of molecular biology and immunologic techniques and the deep research on ocular tumor related genes, it becomes possible to diagnose and treat malignant tumors from the molecular level. The tumor necrosis factor related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor (TNF) super family, is a promising candidate, either alone or in combination with established cancer therapies, since it can initiate apoptosis through the activation of their death receptors. The ability of TRAIL to selectively induce apoptosis of transformed, virus-infected or tumor cells but not normal cells promotes the development of TRAIL-based cancer therapy. Here, we will review TRAIL and its receptors' structure, function, mechanism of action and application in ocular tumors therapy.
大多数眼部肿瘤预后较差，仍是眼科领域的难题。随着分子生物学和免疫技术的迅速发展以及对眼部肿瘤相关基因的深入研究，从分子水平诊断和治疗恶性肿瘤成为可能。肿瘤坏死因子相关凋亡诱导配体（TRAIL）是肿瘤坏死因子（TNF）超家族成员，是一个有前景的候选者，单独或与已有的癌症治疗方法联合使用，因为它可以通过激活其死亡受体引发凋亡。TRAIL选择性诱导转化细胞、病毒感染细胞或肿瘤细胞而非正常细胞凋亡的能力促进了基于TRAIL的癌症治疗的发展。在此，我们将综述TRAIL及其受体的结构、功能、作用机制以及在眼部肿瘤治疗中的应用。
